© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 13, 969-970,
July 3, 2002
© 2002 Oxford University Press
NEWS |
Retinoids and Lung Cancer: Targeting the Right Population
| The first 10% of the full text of this article appears below. |
Enthusiasm for the use of retinoic acids as chemopreventive agents in lung cancer has waned in the last several years after patients in two large trials showed an unexpectedly disappointing response to such treatment. In fact, in both the Alpha-Tocopherol,
-Carotene Cancer Prevention Study and the
-Carotene and Retinol Efficacy Trial (CARET), smokers who took
-carotene supplements had an increased risk of developing and dying of lung cancer.
However, when Jonathan Kurie, M.D., an oncologist at the University of Texas M. D. Anderson Cancer Center, Houston, and colleagues teased apart the data from these studies, they realized that former smokers did not show such increased risk, leaving open the question of whether such treatments may be beneficial to nonsmokers.
| |||||||||||
RAR
and Tumor SuppressionThe Biochemistry Behind the Data